Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain Following Abdominoplasty

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain Following Abdominoplasty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oliceridine (Primary) ; Morphine
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Trevena

Most Recent Events

  • 07 Nov 2017 According to a Trevena media release, results were published in The Journal of Pain Research 2017.
  • 09 May 2017 Results of gastrointestinal safety with oliceridine presented at the 65th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists
  • 17 Oct 2016 According to Trevena media release, the company will webcast and present data at the Annual Meeting of the American Society of Anesthesiologists 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top